openPR Logo
Press release

Drugs for Vulvovaginal Candidiasis Industry – Treatment Analysis,Research,Review to 2023

03-29-2018 04:42 PM CET | Health & Medicine

Press release from: WiseGuy Research Consultants Pvt. Ltd.

/ PR Agency: WiseGuy Research Consultants Pvt. Ltd.
Drugs for Vulvovaginal Candidiasis Market

Drugs for Vulvovaginal Candidiasis Market

WiseGuyReports.Com Publish a New Market Research Report On –“ Drugs for Vulvovaginal Candidiasis Industry – Treatment Analysis,Research,Review to 2023”.

Description:

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Scope of the Report:

This report focuses on the Drugs for Vulvovaginal Candidiasis in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/3091002-global-north-america-europe-and-asia-pacific-south

For more information or any query mail at sales@wiseguyreports.com

Market Segment by Manufacturers, this report covers
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Miconazole
Clotrimazole
Fluconazole
Econazole
Other

Market Segment by Applications, can be divided into
Hospital & Clinic
Pharmacy

There are 15 Chapters to deeply display the global Drugs for Vulvovaginal Candidiasis market.

Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Drugs for Vulvovaginal Candidiasis, with sales, revenue, and price of Drugs for Vulvovaginal Candidiasis, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each region, from 2013 to 2018;

Continue…..

Complete Report Details @ https://www.wiseguyreports.com/reports/3091002-global-north-america-europe-and-asia-pacific-south

Table Of Contents – Major Key Points

1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Introduction
1.2 Market Analysis by Type
1.2.1 Miconazole
1.2.2 Clotrimazole
1.2.3 Fluconazole
1.2.4 Econazole
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Hospital & Clinic
1.3.2 Pharmacy
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force

2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Perrigo
2.2.1 Business Overview
2.2.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 J & J
2.3.1 Business Overview
2.3.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Effik
2.6.1 Business Overview
2.6.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva
2.7.1 Business Overview
2.7.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Continue……

For more information or any query mail at sales@wiseguyreports.com

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Office No.528,Amanora Chambers,Magarpatta Road,Hadapsar,Pune-411028.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Drugs for Vulvovaginal Candidiasis Industry – Treatment Analysis,Research,Review to 2023 here

News-ID: 998392 • Views: 370

More Releases from WiseGuy Research Consultants Pvt. Ltd.

Surveillance 2018 Global Market Net Worth US$ 43600 million Forecast By 2022
WiseGuyReports.Com Publish a New Market Research Report On –“ Surveillance 2018 Global Market Net Worth US$ 43600 million Forecast By 2022”. Description: The Surveillance industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Surveillance market size to maintain the average annual growth rate of 11.54% from 17980 million $ in 2014 to 24950 million $ in 2017, The analysts believe that in the
Tunnel Boring Machine (TBM) Market 2018 Global Analysis By Key Players – Herre …
WiseGuyReports.Com Publish a New Market Research Report On –“ Tunnel Boring Machine (TBM) Market 2018 Global Analysis By Key Players – Herrenknecht, CRTG, CRCHI, Robbins, Tianhe, Komatsu, Mitsubishi”. Description: The Tunnel Boring Machine (TBM) industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Tunnel Boring Machine (TBM) market size to maintain the average annual growth rate of 7.11% from 1880 million $ in
Ultra Fine Copper Powder 2018 Global Market Net Worth US$ 405 million Forecast B …
WiseGuyReports.Com Publish a New Market Research Report On –“ Ultra Fine Copper Powder 2018 Global Market Net Worth US$ 405 million Forecast By 2022”. Description: The Ultra Fine Copper Powder industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Ultra Fine Copper Powder market size to maintain the average annual growth rate of 5.27% from 270 million $ in 2014 to 315 million
Car Leasing Market 2018 Global Share,Trend,Segmentation and Forecast to 2022
WiseGuyReports.Com Publish a New Market Research Report On –“ Car Leasing Market 2018 Global Share,Trend,Segmentation and Forecast to 2022”. Description: The Car Leasing industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Car Leasing market size to maintain the average annual growth rate of X% from XXXX million $ in 2013 to XXXX million $ in 2016, The analysts believe that in the

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning